Non-Small Cell Lung Cancer Treatment Market Share

  • Report ID: 3024
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Non-Small Cell Lung Cancer Treatment Market Share

Geographically, the non-small cell lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific industry is anticipated to hold largest revenue share by 2036, owing to increasing diagnosis rates of non-small cell lung cancer, and need to develop innovative treatment solutions in the region.

Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in lung cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of adoption of advanced immunotherapies along with other therapies, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the non-small cell lung cancer treatment market on account of its proven success in terms of research & development and a high prevalence of non-small lung cancer in the region. In Europe, lung cancer is the leading cause of cancer-related deaths and about 85% of all lung cancer cases are classified as those of non-small cell lung cancer.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3024
  • Published Date: Sep 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of non-small cell lung cancer, and the growing awareness about the disease are the key factors driving market growth.

The market is anticipated to attain a high CAGR over the forecast period, i.e., 2021-2029.

The limited treatment options for non-small cell lung cancer and lack of awareness about the disease in lower economic regions are estimated to hamper market growth.

The market in Asia Pacific region will provide ample growth opportunities owing to the increasing diagnosis rates of non-small cell lung cancer.

The major players dominating the non-small cell lung cancer treatment market are Genentech, Inc., Celgene Corporation, AstraZeneca plc, and Elli Lilly & Company among others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample